title: Potential causes of weight gain in type 1 diabetes mellitus.
abstract: OBJECTIVE
  To investigate the potential causes of weight gain with insulin therapy and improved diabetic control in type 1 diabetes mellitus.
  
  
  METHODS
  This was an open-label prospective study of insulin therapy of 6 months duration in an academic medical centre. Twenty-one subjects with type 1 diabetes were enrolled. The goal was to achieve an haemoglobin A1c (HbA1c) in the range of individuals without diabetes (<5.6%). At baseline, 3 and 6 months, weight, resting energy expenditure, appetite assessment, food intake, activity level, HbA1c and 24-h glycosuria and urea nitrogen were measured. Plasma leptin, ghrelin and adiponectin levels and body fat were measured at baseline and 6 months.
  
  
  RESULTS
  At baseline, average weight was 73.7 +/- 17.4 kg and HbA1c was 10.0 +/- 2.2%. Weight increased by 2.15 kg (2.69% of baseline) by 6 months whereas the HbA1c dropped by 1.71% (16.3%) to 7.9%. Energy intake differences between 3 and 6 months had a negative correlation with weight gain, but the changes in glycosuria, appetite scores and the frequency of hypoglycaemia did not correlate with weight gain. Glycaemic control did not correlate with weight change but tended to correlate with fat mass increase (p = 0.064; r = -0.51). An increase in the activity levels between 3 and 6 months correlated with decreasing fat mass (p = 0.037; r = -0.74). The changes in the appetite scores had a negative correlation with fat mass gain (p = 0.035; r = -0.61). The changes in lean body mass correlated with protein and total energy intake (p = 0.007, r = 0.85 and p = 0.003, r = 0.73 respectively). The changes in leptin levels correlated with weight gain.
  
  
  CONCLUSIONS
  The lipogenic effect of insulin with subsequent increase in fat mass may be the primary cause of this weight gain that can be attenuated by the increases in the activity levels. The negative correlation of energy intake and appetite scores with fat mass gain suggests that they do not play a significant role in fat mass gain whereas energy intake did correlate with lean body mass gain.
authors.affiliation: Department of Internal Medicine, University of Texas Southwestern Medical Center in Dallas, TX 75390-8858, USA.
authors.forename: A N
authors.initials: AN
authors.lastname: Jacob
authors.forename: K
authors.initials: K
authors.lastname: Salinas
authors.forename: B
authors.initials: B
authors.lastname: Adams-Huet
authors.forename: P
authors.initials: P
authors.lastname: Raskin
mesh_terms: D000328:Adult; D001066:Appetite / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy / Q000503:physiopathology*; D002149:Energy Intake / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006029:Glycosuria / Q000503:physiopathology; D006801:Humans; D007328:Insulin / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts; D005082:Physical Exertion; D011446:Prospective Studies; D015430:Weight Gain / Q000187:drug effects*
chemical_list: D006442:Glycated Hemoglobin; D007328:Insulin